Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Financial Outlook | Analysts project a cash runway into 2026, with price targets around $5.00. Learn how Sana's future value hinges on clinical success and market penetration. |
Market Differentiation | Delve into how Sana's unique hypoimmune platform could set it apart in the competitive cell therapy landscape, offering off-the-shelf products without immunosuppression. |
Pipeline Progress | Explore Sana's strategic focus on T1D and AID programs, with promising results from UP421 and anticipated data releases for SC291 and SC262 in 2025. |
Hypoimmune Platform | Sana's innovative technology aims to produce immune-evading cells, potentially revolutionizing treatments for Type 1 Diabetes and autoimmune diseases. |
Metrics to compare | SANA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSANAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −4.1x | −0.5x | |
PEG Ratio | −0.07 | 0.00 | 0.00 | |
Price / Book | 3.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 1,682.3x | 3.0x | |
Upside (Analyst Target) | 215.8% | 217.7% | 51.5% | |
Fair Value Upside | Unlock | 35.8% | 9.4% | Unlock |